H-1.1, r. 1 - Regulation respecting the conditions for compensation to victims of a Héma-Québec product

Section 1 Disposition versions

2012-09-01

1. For the purposes of section 54.1 of the Act, the following immunological and hemodynamic reactions, associated with the normal constituents of blood products in relation to the standards in force when a Héma-Québec product is administered, are adverse effects not constituting a bodily injury:

— haemolytic reaction;

— allergic reaction;

— anaphylactic reaction;

— febrile non-haemolytic transfusion reaction;

— circulatory overload;

— graft disease against the secondary host following transfusion or graft;

— transfusion-related acute lung injury (TRALI);

— post-transfusion hypertensive or hypotensive reactions;

— post-transfusion alloimmune thrombocytopenia or neutropenia;

— erythrodermia;

— hemochromatosis;

— transient transfusion-related acute dyspnea;

— cephalgia;

— aseptic meningitis;

— vagal shock;

— post-transfusion purpura;

— development of irregular antibodies;

— post-transfusion thrombotic and vascular events;

— complications associated with a massive transfusion, such as metabolic acidosis, hypocalcemia, hypomagnesemia and hyperkalemia.

O.C. 468-2011, s. 1.